Key result
Pegylated interferon plus ribavirin retreatment in hepatitis C nonresponders was associated with a 16.6% incidence of psychiatric side effects over 24 weeks.
Why the study?
Does pegylated interferon plus ribavirin retreatment cause a high incidence of mental disorders in hepatitis C virus-infected interferon-nonresponder patients?
Cohort (n=30)
Does pegylated interferon plus ribavirin retreatment cause a high incidence of mental disorders in hepatitis C virus-infected interferon-nonresponder patients?
The risk of acquiring serious psychiatric symptoms during retreatment with interferon-alpha in hepatitis C patients may not be higher than during the first antiviral therapy.
Answers are grounded in this paper and cite their sources.
Psychiatric monitoring remains prudent during interferon retreatment; leaves open relevance versus direct-acting antivirals.
OBJECTIVE: Evaluate the incidence of mental disorders using pegylated interferon plus ribavirin retreatment in nonresponder hepatitis C virus-infected patients. METHOD: The Mini-International Neuropsychiatric Interview (MINI) was used to evaluate 30 hepatitis C virus-infected interferon-nonresponder patients at baseline and following 4, 12 and 24 weeks of pegylated interferon retreatment. RESULTS: During the pegylated interferon/ribavirin retreatment, 5(16.6%) patients developed psychiatric side effects: 3(10%) were diagnosed with major depressive disorder, 1(3.3%) had a brief psychotic disorder and 1(3.3%) presented with panic attacks. CONCLUSION: This is the first prospective study evaluating the incidence of neuropsychiatric side effects during interferon retreatment of hepatitis C virus-infected patients, suggesting that the risk of acquiring serious psychiatric symptoms during retreatment with interferon-alpha (IFN-alpha) may not be higher than during the first antiviral therapy. This finding challenges the hypothesis that during a second treatment with IFN-alpha, patients with hepatitis C may be at greater risk for neuropsychiatric side effects than naïve patients.
No takes yet. Share an insight, caveat, or question.
Quarantini et al. (2007) conducted a cohort in Hepatitis C virus infection (n=30). Pegylated interferon plus ribavirin retreatment was evaluated on Incidence of psychiatric side effects. Pegylated interferon plus ribavirin retreatment in hepatitis C nonresponders was associated with a 16.6% incidence of psychiatric side effects over 24 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: